6620 Share Price Performance
NT$67.50
7.30 (12.13%)
Price NT$67.50
Share Pricen/a
Handa Pharmaceuticals, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
6620 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Handa Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 14, 2026
- 4.77
- 84.53%
- 43.36%
- 0%
About 6620
- Founded
- 2014
- Employees
- n/a
- CEO
- WebsiteView website
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease; HND-004 for treating diabetes; HND-032 for smoking cessation; and HND-026, a GI drug. Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.
